CeQur, a medical device company based in Horw, Switzerland, has raised $116.4 million in funding to accelerate the commercialization of its innovative insulin delivery solution, CeQur Simplicity.
The financing round was co-led by Athos Biopharma GmbH and Mirae Asset Financial Group, with participation from existing investors VI Partners AG, Endeavour Vision SA, KCK Ltd, and Pappas Capital LLC.
Transforming Insulin Delivery
CeQur Simplicity is a wearable, disposable insulin delivery device designed for people with Type 2 diabetes who require multiple daily injections. The device allows patients to administer insulin discreetly and conveniently, reducing the burden of frequent injections and improving adherence to treatment plans.
By offering a simple and user-friendly alternative to traditional insulin pens and syringes, CeQur aims to enhance the quality of life for millions managing Type 2 diabetes worldwide.
Advertisement
Allocation of Funds
The newly secured capital will be used to:
- Expand Commercialization: Accelerate the launch and distribution of CeQur Simplicity in key markets across the United States and Europe.
- Scale Manufacturing: Increase production capacity to meet growing demand.
- Advance Clinical Studies: Continue research to further validate the efficacy and safety of the device.
- Enhance Awareness: Invest in marketing and educational initiatives to inform healthcare providers and patients about the benefits of CeQur Simplicity.
Leadership Remarks
CEO Bradley Paddock commented:
“We are excited to have the support of such esteemed investors who share our commitment to improving insulin delivery for those living with Type 2 diabetes. This significant investment enables us to expand our reach and provide a discreet, convenient solution that can positively impact patient outcomes.”
About CeQur
Founded in 2008, the company is dedicated to developing and bringing to market advanced yet straightforward insulin delivery devices. The company’s mission is to simplify diabetes management by providing solutions that reduce the complexity of insulin therapy, thereby promoting better health and well-being for patients.e company is well-positioned to redefine how AI can support healthcare professionals and patients alike.
